Posted by Michael Wonder on 28 Sep 2023
Alpha Cognition announces submission of new drug application to the FDA for ALPHA-1062 for mild to moderate Alzheimer’s disease
27 September 2023 - Alpha Cognition is pleased to announce the submission of a new drug application to the US FDA for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s disease.
ALPHA-1062, a pro-drug of galantamine, is uniquely designed to reduce gastro-intestinal adverse effects by remaining inert as it passes through the stomach.
